Lenvatinib Mesylate-impurities | Pharmaffiliates

lenvatinib mesylate and its Impurities

Lenvatinib is approved for the treatment of differentiated thyroid cancer that is either locally recurrent or metastatic, progressive, and did not respond to treatment with radioactive iodine. It is an anti-cancer drug. Reference standards of Lenvatinib Mesylate API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.

Displaying 1 results for lenvatinib mesylate Impurities
PA 39 03000

Lenvatinib Mesylate - API Standards

Lenvatinib Mesylate

  • Catalogue No.:PA 39 03000

  • CAS :


  • Molecular Formula : C22H23ClN4O7S

  • Molecular Weight : 522.96